Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01).

ABSTRACT:

Background

Nab-paclitaxel (nab-PTX) has better transfer to tumor tissue than cremophor-based paclitaxel. It suggests that the optimum dose of nab-PTX might be lower than the dose and schedule that is widely used. We designed a randomized phase II trial to examine the clinical utility and safety of nab-PTX in patients with previously treated advanced non-small cell lung cancer (NSCLC).

Methods

Patients were randomly allocated (1:1) to receive nab-PTX monotherapy at 100 mg/m² (group A) or 70 mg/m² (group B). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and adverse events (AEs).

Results

Finally, 81 patients were randomized. Similar results were observed i

SUBMITTER: Takeuchi S 

PROVIDER: S-EPMC10166935 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature